* To take over from interim head on Nov. 1
* Brandicourt to drive growth from promising new drugs
* Has been member of Pfizer executive leadership team
FRANKFURT, Sept 30 (Reuters) - Germany's Bayer named Pfizer executive Olivier Brandicourt as the newhead of its healthcare division, where he will oversee themarket launch of a range of potential blockbusters.
He will take over from Bayer Healthcare interim headWolfgang Plischke on Nov. 1, Germany's largest drugmaker said ina statement on Monday.
Brandicourt, who was a member of Pfizer's executiveleadership team, will be responsible for taking new drugs tomarket, including stroke prevention pill Xarelto, eye drug Eyleaand cancer treatment Stivarga and to translate successful drugtrials into revenue growth.
A 30 percent increase in Bayer's shares over the last 12months shows high expectations that the new drugs will offset anexpected decline in sales of its multiple sclerosis drug andsome birth control pills, which are hit by rival products.
At 0707 GMT, the shares slipped 0.5 percent to 87.06 euros,the STOXX Europe 600 Health Care index edged 0.1 percentlower.
CEO Marijn Dekkers has said that while Bayer has been strongin research and development, it needs to do better at marketingits products.
The group's five most promising new pharmaceuticals have acombined peak sales potential of more than 5.5 billion euros($7.45 billion), according to Bayer.
The previous head of Bayer Healthcare, Joerg Reinhardt, quitin February to become chairman of Novartis.
- Health Care Industry
- Pharmaceuticals & Drug Trials